Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D. Wiviott, Marc S. Sabatine, Thomas A. Zelniker et al.|New England Journal of Medicine|2018Cited by 6.3k
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialOfri Mosenzon, Itamar Raz, Stephen D. Wiviott et al.|The Lancet Diabetes & Endocrinology|2019Cited by 673
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trialOfri Mosenzon, Stephen C. Bain, Hiddo J.L. Heerspink et al.|Diabetes Obesity and Metabolism|2020Cited by 24
Author response for "Cardiovascular and renal outcomes by baseline albuminuria status and renal function — results from the <scp>LEADER</scp> randomized trial"Ofri Mosenzon, Itamar Raz, Stephen C. Bain et al.|Unknown|2020Cited by 0